Targovax Presents at DNB 9th Annual Nordic Healthcare Conference

News provided by

Dec 12, 2018, 11:01 ET

OSLO, Norway, Dec. 12, 2018 /PRNewswire/ --

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that CEO Øystein Soug presented today at DNB 9th Annual Nordic Healthcare Conference in Oslo, Norway.

The presentation provided a corporate overview, highlighting the Company's two platform technologies including clinical data from its lead pipeline asset, ONCOS-102, an oncolytic adenovirus, and the TG cancer vaccine program that targets tumors that express mutated forms of RAS - mutations known to drive cancer.

Please see the presentation attached. TRVX DNB presentation

The presentation is also available to download at www.targovax.com.

CONTACT:

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47-922-61-624
Email: [email protected]

Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47-9300-1773
Email: [email protected]

Simon Conway/Stephanie Cuthbert - FTI Consulting (International)
Phone: +44-20-3727-1000
Email: [email protected]